Journal
NATURE REVIEWS NEUROSCIENCE
Volume 18, Issue 12, Pages 753-769Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/nrn.2017.136
Keywords
-
Categories
Funding
- MRC [G0601744, G0802545] Funding Source: UKRI
- Medical Research Council [G0601744, G0802545, MC_PC_12009] Funding Source: Medline
- Medical Research Council [G0700711B, G0601744, MC_PC_12009, G0802545] Funding Source: researchfish
- Wellcome Trust [104783/Z/14/Z] Funding Source: researchfish
- Wellcome Trust [104783/Z/14/Z] Funding Source: Wellcome Trust
Ask authors/readers for more resources
Although the core concept of remyelination - based on the activation, migration, proliferation and differentiation of CNS progenitors - has not changed over the past 20 years, our understanding of the detailed mechanisms that underlie this process has developed considerably. We can now decorate the central events of remyelination with a host of pathways, molecules, mediators and cells, revealing a complex and precisely orchestrated process. These advances have led to recent drug-based and cell-based clinical trials for myelin diseases and have opened up hitherto unrecognized opportunities for drug-based approaches to therapeutically enhance remyelination.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available